jRCT2031220610进行中（未招募）不适用
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Alopecia Areata
Bristol-Myers Squibb0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 9
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 65age old under（—）
- 性别
- All
入选标准
- •Documented clinical diagnosis of AA for at least 6 months
- •Alopecia Areata Investigator Global Assessment ( AA-IGA)
排除标准
- •Other active skin diseases affecting the scalp that in the opinion of the investigator may interfere with accurate assessment of SALT score
- •History or evidence of active infection and/or febrile illness
- •Any ongoing treatment known to affect hair growth
结局指标
主要结局
-
SALT score safety and tolerability
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE
(POETYK SLE-2) (IM011-247)Systemic Lupus ErythematosusjRCT2011230001Bristol-Myers Squibb490
招募中
不适用
Investigation of the usefulness of deucravacitinib in early onset psoriasisPsoriasis vulgarisjRCTs041240089100
已完成
4 期
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisPsoriasisNCT05478499Bristol-Myers Squibb154
进行中（未招募）
3 期
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT05617677Bristol-Myers Squibb516
进行中（未招募）
3 期
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT05620407Bristol-Myers Squibb513